Target intelligence / Profile preview

Coxsackievirus and adenovirus receptor (CXADR) (CAR)

Target
CAR
Molecular classification
Receptor, Cell adhesion molecule, Immunoglobulin superfamily
01

Overview

The Coxsackievirus and adenovirus receptor (CAR), encoded by the CXADR gene, is a 46 kDa type I transmembrane protein and a member of the immunoglobulin superfamily [18]. It is primarily localized at the tight junctions of epithelial and endothelial cells, where it functions as a homophilic cell adhesion molecule essential for maintaining tissue integrity and regulating paracellular permeability [3, 4]. CAR is most notably recognized as the primary cellular attachment receptor for group B coxsackieviruses and many adenoviruses, including the serotype 5 (Ad5) widely used in gene therapy and oncolytic virotherapy [2, 6]. In oncology, CAR serves as the entry point for oncolytic adenoviruses such as CG7870, which utilize their fiber knob domain to bind the receptor and initiate infection [5, 16]. However, the expression of CAR is often downregulated in advanced or metastatic tumors, which can limit the efficacy of these viral therapies and has led to the development of modified fiber knob variants [1, 13]. Beyond its role in infection, CAR is involved in cardiac development and the transmigration of leukocytes during inflammatory responses [7, 18]. Therapeutic strategies targeting CAR include the use of oncolytic viruses for cancer treatment and soluble CAR-Fc fusions to block viral infections like myocarditis [21, 23]. Safety concerns for CAR-targeted therapies include off-target effects in the heart and liver, as well as the sequestration of viral particles by CAR-expressing erythrocytes [9, 18].

Other names
CXADRCARHCARCoxsackie virus and adenovirus receptorIg-like cell adhesion moleculeCXADR Ig-like cell adhesion molecule
02

Mechanism of action

Viral attachment and receptor-mediated endocytosis; Competitive inhibition of viral binding; Downregulation of receptor expression

03

Biological functions

Cell adhesionViral entryTight junction integrityLeukocyte transmigrationSignal transduction
04

Disease associations

InfectionCancerCardiovascular diseaseInflammation
05

Safety considerations

Off-target infection of normal tissuesHepatotoxicitySequestration by erythrocytesPre-existing anti-adenovirus immunity
06

Interacting drugs

CG7870 (CV787)

5 more in the full profile.

07

Biomarkers

CAR expression levelProstate-specific antigen (PSA)

Beyond the preview

Go deeper on Coxsackievirus and adenovirus receptor (CXADR) (CAR).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Coxsackievirus and adenovirus receptor (CXADR) (CAR).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call